A COST PER RESPONDER ANALYSIS OF SECUKINUMAB VS. ADALIMUMAB BASED ON A MATCHING-ADJUSTED INDIRECT COMPARISON OF EFFICACY DATA FOR THE TREATMETN OF PSORIATIC ARTHRITIS AT 48 WEEKS FROM THE IRISH PAYER PERSPECTIVE

被引：1

作者：

Gunda, P. ^{[1
]}

Nikoglou, E. ^{[2
]}

Jugl, S. M. ^{[3
]}

Murphy, A. ^{[4
]}

机构：

[1] Novartis Healthcare Pvt Ltd, Prod Life Cycle Serv NBS, Hyderabad, Andhra Pradesh, India

[2] Novartis Global Serv Ctr Dublin, Prod Lifecycle Serv NBS, Dublin, Ireland

[3] Novartis Pharma AG, Basel, Switzerland

[4] Novartis Ireland Ltd, Dublin, Ireland

来源：

关键词：

D O I：

10.1016/j.jval.2017.08.758

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PMS37

引用

页码：A532 / A532

页数：1